During the last few years, acetarsone, chemically known as 3-acetyl-amino-4-hydroxyphenyl-1-arsonic acid, appears to have established a place among the prominent therapeutic agents in the treatment of syphilis. It has been more extensively used abroad than in this country. It is known also as stovarsol. The formula or preparation was developed by Ehrlich1 in 1911. It is believed that he was not satisfied with the practical therapeutic value of the preparation because of its toxic reactions in experiments with mice. No further study of the compound was made until its reinvestigation by Fourneau2 in 1921.
In 1922, Levaditi and Navarro-Martin3 proved that acetarsone, injected subcutaneously in doses of from 0.1 to 0.2 Gm. per kilogram of body weight, has a curative action in experimental syphilis of the rabbit. In addition, Levaditi and Navarro-Martin4 found that the oral administration of the preparation brings about the healing of syphilitic
GRIGGS LH, SCHAMBERG JF. ACETARSONE IN THE TREATMENT OF NEUROSYPHILIS. Arch Derm Syphilol. 1934;29(5):645–652. doi:10.1001/archderm.1934.01460110003001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: